{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:54:54Z","timestamp":1781762094078,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dasatinib is a favorable option for patients with chronic-phase chronic myeloid leukemia (CML-CP) who have an inadequate response, treatment intolerance, or are attempting treatment-free remission (TFR). Dasatinib dose reduction is a strategy to improve tolerability while maintaining efficacy in first-line settings or patients with a stable molecular response. However, whether low-dose dasatinib is safe and effective in second-line or later setting for patients with CML-CP remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 53 patients with CML-CP who switched to low-dose dasatinib due to inadequate molecular response (n = 37), treatment intolerance (n = 13), or to re-induce a deeper molecular response (n = 3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 37 patients who had not achieved major molecular response (MMR) before switching, 10 patients (27.0%) attained MMR, 12 patients (32.4%) achieved deep molecular response (DMR\/MR4), and 11 patients (29.7%) reached molecular response 4.5 (MR4.5) following low-dose dasatinib therapy. Notably, 81.8% of patients with only baseline MMR improved to MR4 or MR4.5 after switching to low-dose dasatinib. One patient lost MR4 while receiving dasatinib at 50\u00a0mg\/day and subsequently switched to nilotinib. All three patients who were switched to re-induce deeper molecular responses successfully re-attained MR4.5 after switching to low-dose dasatinib. Adverse events resolved in all 13 patients who switched due to prior TKI intolerance, and no worsening grade 2 or more adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that low-dose dasatinib for selected patients with CML-CP in second-line therapy or beyond may be safe and effective under close monitoring. Nevertheless, multicenter prospective clinical trials are needed to validate the efficacy and safety of low-dose dasatinib therapy in second-line treatment settings or beyond in CML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1734319","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:30:29Z","timestamp":1781760629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose dasatinib in second-line therapy or beyond for the treatment of chronic-phase chronic myeloid leukemia: a real-world cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yilin","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]},{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Central Hospital of Wuhan","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41375-021-01272-8","article-title":"Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors","volume":"35","author":"Baccarani","year":"2021","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1080\/10428194.2017.1357178","article-title":"Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors","volume":"59","author":"Cayssials","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.3324\/haematol.2022.280637","article-title":"Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China","volume":"107","author":"Chen","year":"2022","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1101743","DOI":"10.3389\/fphar.2023.1101743","article-title":"Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: results from real-world practice","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"E375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.17286","article-title":"TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia","volume":"193","author":"Claudiani","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/Jco.2015.64.8899","article-title":"Final 5-Year study results of DASISION: the dasatinib Versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/17474086.2021.1886918","article-title":"Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"14","author":"Efficace","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.3390\/cancers12092521","article-title":"Incidences of Deep Molecular Responses and Treatment-Free Remission in de novo CP-CML Patients","volume":"12","author":"Etienne","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3324\/haematol.2018.194522","article-title":"Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data","volume":"103","author":"Fassoni","year":"2018","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3324\/haematol.2018.205054","article-title":"Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice","volume":"104","author":"Fava","year":"2019","journal-title":"Haematologica"},{"key":"B93","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2169\/internalmedicine.9035-17","article-title":"The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: the LD-CML study of the kanto CML study group","volume":"57","author":"Iriyama","year":"2018","journal-title":"Intern. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E260","DOI":"10.1002\/ajh.25908","article-title":"Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs","volume":"95","author":"Iurlo","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s00432-017-2517-0","article-title":"Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia","volume":"143","author":"Jiang","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/14740338.2024.2368822","article-title":"Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety","volume":"23","author":"Lagan\u00e0","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/ejh.70006","article-title":"Treatment Free Remission (TFR) in chronic phase-chronic myeloid leukemia (CP-CML): analysis of predictive factors and novel baseline scoring system to predict molecular relapse","volume":"115","author":"Lagan\u00e0","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e35565","DOI":"10.1002\/cncr.35565","article-title":"Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia","volume":"131","author":"Li","year":"2025","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-Free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann. Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/jco.23.01647","article-title":"European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"key":"B27","first-page":"318","article-title":"Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED)","volume":"130","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjh.17654","article-title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","volume":"194","author":"Rousselot","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/jco.2016.67.4184","article-title":"Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia","volume":"34","author":"Winn","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12672-024-01444-9","article-title":"Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a systematic review and meta-analysis","volume":"15","author":"Zheng","year":"2024","journal-title":"Discov. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1734319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:30:30Z","timestamp":1781760630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1734319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":32,"alternative-id":["10.3389\/fphar.2026.1734319"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1734319","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1734319"}}